A citation-based method for searching scientific literature

Andrew McGovern, Michael Feher, Neil Munro, Simon de Lusignan. Diabetes Ther 2017
Times Cited: 4







List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
75

Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK.
Andrew McGovern, William Hinton, Ana Correa, Neil Munro, Martin Whyte, Simon de Lusignan. BMJ Open 2016
34
50



Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile.
Ana Correa, William Hinton, Andrew McGovern, Jeremy van Vlymen, Ivelina Yonova, Simon Jones, Simon de Lusignan. BMJ Open 2016
119
50

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
50




Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal. Lancet Diabetes Endocrinol 2016
278
50

DECLARE-TIMI 58: Participants' baseline characteristics.
Itamar Raz, Ofri Mosenzon, Marc P Bonaca, Avivit Cahn, Eri T Kato, Michael G Silverman, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding,[...]. Diabetes Obes Metab 2018
73
50

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson,[...]. Lancet Diabetes Endocrinol 2017
199
50

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
230
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
50

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Kåre I Birkeland, Johan Bodegard, Anna Norhammar, Josephina G Kuiper, Elena Georgiado, Wendy L Beekman-Hendriks, Marcus Thuresson, Marc Pignot, Ron M C Herings, Adriaan Kooy. Diabetes Obes Metab 2019
40
50

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
527
25

Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Janice M S Lopez, Brian Macomson, Varun Ektare, Dipen Patel, Marc Botteman. Am Health Drug Benefits 2015
13
25

Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors.
C Daousi, I F Casson, G V Gill, I A MacFarlane, J P H Wilding, J H Pinkney. Postgrad Med J 2006
162
25


SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Muhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, Ralph A DeFronzo. Diabetes Care 2016
189
25

Integrating electronic health record information to support integrated care: practical application of ontologies to improve the accuracy of diabetes disease registers.
Siaw-Teng Liaw, Jane Taggart, Hairong Yu, Simon de Lusignan, Craig Kuziemsky, Andrew Hayen. J Biomed Inform 2014
22
25

Routinely-collected general practice data are complex, but with systematic processing can be used for quality improvement and research.
Simon de Lusignan, Nigel Hague, Jeremy van Vlymen, Pushpa Kumarapeli. Inform Prim Care 2006
20
25


CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
512
25

Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
Heleen G M van Haalen, Marjolein Pompen, Klas Bergenheim, Phil McEwan, Rebecca Townsend, Marina Roudaut. Clin Drug Investig 2014
34
25

Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Kristina Johnsson, Eva Johnsson, Traci A Mansfield, Yshai Yavin, Agata Ptaszynska, Shamik J Parikh. Postgrad Med 2016
28
25

Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon.
Vishal Sehgal, Sukhminder Jit Singh Bajwa, Rinku Sehgal, John A Consalvo. J Pharmacol Pharmacother 2014
8
25


Creating and using real-world evidence to answer questions about clinical effectiveness.
Simon de Lusignan, Laura Crawford, Neil Munro. J Innov Health Inform 2015
34
25

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.
Hassan Rahmoune, Paul W Thompson, Joanna M Ward, Chari D Smith, Guizhu Hong, John Brown. Diabetes 2005
506
25

Basing approval of drugs for type 2 diabetes on real world outcomes.
Andrew McGovern, Robert Hinchliffe, Neil Munro, Simon de Lusignan. BMJ 2015
5
25

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Michael Fischereder, Ulf Schönermarck. N Engl J Med 2016
6
25

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Pantelis A Sarafidis, Apostolos Tsapas. N Engl J Med 2016
15
25

Health monitoring in sentinel practice networks: the contribution of primary care.
D M Fleming, F G Schellevis, W J Paget. Eur J Public Health 2003
36
25

Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.
Julia Hippisley-Cox, Carol Coupland, Yana Vinogradova, John Robson, Rubin Minhas, Aziz Sheikh, Peter Brindle. BMJ 2008
826
25

Trends in the epidemiology of cardiovascular disease in the UK.
Prachi Bhatnagar, Kremlin Wickramasinghe, Elizabeth Wilkins, Nick Townsend. Heart 2016
119
25

An integrated organisation-wide data quality management and information governance framework: theoretical underpinnings.
Siaw-Teng Liaw, Christopher Pearce, Harshana Liyanage, Gladys S S Liaw, Simon de Lusignan. Inform Prim Care 2014
11
25

Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK.
Roger Williams, Graeme Alexander, Iain Armstrong, Alastair Baker, Neeraj Bhala, Ginny Camps-Walsh, Matthew E Cramp, Simon de Lusignan, Natalie Day, Anil Dhawan,[...]. Lancet 2018
82
25





The representativeness of sentinel practice networks.
D M Fleming, J Miles. J Public Health (Oxf) 2010
26
25


Uptake of a Dashboard Designed to Give Realtime Feedback to a Sentinel Network About Key Data Required for Influenza Vaccine Effectiveness Studies.
Sameera Pathirannehelage, Pushpa Kumarapeli, Rachel Byford, Ivelina Yonova, Filipa Ferreira, Simon de Lusignan. Stud Health Technol Inform 2018
26
25

Representativeness of patients and providers in the Canadian Primary Care Sentinel Surveillance Network: a cross-sectional study.
John A Queenan, Tyler Williamson, Shahriar Khan, Neil Drummond, Stephanie Garies, Rachael Morkem, Richard Birtwhistle. CMAJ Open 2016
56
25




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.